—— 要投稿,上万维,轻松学术交流

严正声明

本站非期刊官网,非中介代理,
不向作者收取任何费用!
举报微信:13140028228 冯老师

态度公正、信息求实、投稿自助、使用免费
Immunotherapy《免疫疗法》
年18期 - 英国
  • Immunotherapy《免疫疗法》
  • SCIE外文期刊
  • 期发文量9
  • 国人占比22.22%
  • 维普目次
  • 投稿方式--官网投稿
  • 期刊属性

  • 中科分区:4区
    OA期刊:混合
  • 综述期刊:
    TOP期刊:
  • 期均国文:2
    环比增速:100.00%
  • 期刊信息

  • 研究方向:医学-IMMUNOLOGY 免疫学
  • 国际刊号:ISSN1750-743X;EISSN1750-7448
  • 期刊语言:英语
    出版地区:英国
  • 投稿网址:https://mc04.manuscriptcentral.com/fm-imt
  • 电子邮箱:
  • 期刊官网:https://www.futuremedicine.com/loi/imt
  • 作者指南:
  • 出版商网址:http://www.futuremedicine.com
  • 出版地址:FUTURE MEDICINE LTD, UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB
  • 期刊简介:Immunotherapy《免疫疗法》(一年18期). The field of immunotherapy is moving forward at an unprecedented rate, and a range of therapeutic approaches are now used in clinical practice, often with outstanding success. Cancer immunotherapies are coming of age and have the potential to produce long-lasting remission, often with fewer side effects and reduced drug resistance compared with conventional therapies.

  • 万维提示


  • 1、投稿方式:在线投稿

    2期刊网址:

    https://www.futuremedicine.com/journal/imt

    3投稿网址:

    https://mc04.manuscriptcentral.com/fm-imt

    4、官网邮箱:r.gilroy@futuremedicine.com

    5、期刊刊期:一年出版18期。

    2021年8月17日星期

                                     

     

    期刊信息【官网信息】

     

    Immunotherapy

    Aims & Scope

    The field of immunotherapy is moving forward at an unprecedented rate, and a range of therapeutic approaches are now used in clinical practice, often with outstanding success. Cancer immunotherapies are coming of age and have the potential to produce long-lasting remission, often with fewer side effects and reduced drug resistance compared with conventional therapies. Recently the FDA has approved immunotherapies for melanoma and lung cancer, and clinical trials are yielding positive results for a range of cancer types, reflecting the promising new role for immunotherapy in cancer treatment. Immunotherapies are also being applied in a variety of other disease areas, including allergy, rheumatoid disease, autoimmunity and transplantation, as well as in many infections, such as HIV and hepatitis.

    Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field.

    Articles published in Immunotherapy include key areas such as:

    Cancer immunotherapy, including checkpoint blockade, cancer vaccines, adoptive T cell therapy, monoclonal antibodies and cytokines

    Combined chemo/radio immunotherapy in cancer treatment

    Biomarkers for personalized cancer immunotherapy

    Allergen immunotherapy, including sublingual, subcutaneous and oral immunotherapy

    Restorative immunotherapy for HIV and other immunocompromised patients

    Suppressive immunotherapy for autoimmunity diseases and transplantation

    Basic science of immunotherapeutic approaches 

    Drug–immune system interactions

    Drug delivery systems, drug combinations and drug–drug interactions

    Summaries evaluating newly approved immunotherapeutic agents

    Newly identified immune targets of drugs

    Results of recent findings and clinical trials relevant to the field of immunotherapy

    Post marketing research, including adverse events, drug safety, pharmacoeconomics, cost–benefit issues, real-world evidence and outcomes research

    Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal's Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.







欢迎点评!让信息更透明,使投稿更轻松!
  • 审稿时间:
    是否录用:
  • 见刊周期:
    查重要求:
  • 有无课题:
    有无回复:
  • 我的学历:
    我的职称:
  • 审稿费用:
    版面费用:
  • 稿       费:
    稿件字数:
  • 投稿难度:
  • 该刊可发:
  • 投稿主题:
匿名: 验证码: 点击切换验证码
    评分:0

    验证码: 点击切换验证码